HRP20191933T1 - Kombinacija anti-cd30xcd16a antitijela s antagonističkim anti-pd-1 antitijelom za terapiju - Google Patents

Kombinacija anti-cd30xcd16a antitijela s antagonističkim anti-pd-1 antitijelom za terapiju Download PDF

Info

Publication number
HRP20191933T1
HRP20191933T1 HRP20191933TT HRP20191933T HRP20191933T1 HR P20191933 T1 HRP20191933 T1 HR P20191933T1 HR P20191933T T HRP20191933T T HR P20191933TT HR P20191933 T HRP20191933 T HR P20191933T HR P20191933 T1 HRP20191933 T1 HR P20191933T1
Authority
HR
Croatia
Prior art keywords
combination
use according
antibody
cd16a
seq
Prior art date
Application number
HRP20191933TT
Other languages
English (en)
Croatian (hr)
Inventor
Martin Treder
Uwe Reusch
Jens-Peter Marschner
Stefan Knackmuss
Original Assignee
Affimed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15166303.6A external-priority patent/EP3091031A1/en
Application filed by Affimed Gmbh filed Critical Affimed Gmbh
Publication of HRP20191933T1 publication Critical patent/HRP20191933T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20191933TT 2015-05-04 2016-05-04 Kombinacija anti-cd30xcd16a antitijela s antagonističkim anti-pd-1 antitijelom za terapiju HRP20191933T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15166303.6A EP3091031A1 (en) 2015-05-04 2015-05-04 Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor
EP16152650 2016-01-25
PCT/EP2016/060113 WO2016177846A1 (en) 2015-05-04 2016-05-04 Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy
EP16723968.0A EP3292153B1 (en) 2015-05-04 2016-05-04 Combination of a cd30xcd16a antibody with an anti-pd-1 antagonistic antibody for therapy

Publications (1)

Publication Number Publication Date
HRP20191933T1 true HRP20191933T1 (hr) 2020-01-10

Family

ID=56026814

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191933TT HRP20191933T1 (hr) 2015-05-04 2016-05-04 Kombinacija anti-cd30xcd16a antitijela s antagonističkim anti-pd-1 antitijelom za terapiju

Country Status (20)

Country Link
US (1) US11167029B2 (enExample)
EP (1) EP3292153B1 (enExample)
JP (1) JP6609784B2 (enExample)
CN (1) CN107847587B (enExample)
AU (1) AU2016257334B2 (enExample)
BR (1) BR112017023579A2 (enExample)
CA (2) CA3219372A1 (enExample)
CY (1) CY1122283T1 (enExample)
DK (1) DK3292153T3 (enExample)
ES (1) ES2754557T3 (enExample)
HR (1) HRP20191933T1 (enExample)
HU (1) HUE045866T2 (enExample)
LT (1) LT3292153T (enExample)
PL (1) PL3292153T3 (enExample)
PT (1) PT3292153T (enExample)
RS (1) RS59489B1 (enExample)
RU (1) RU2761352C2 (enExample)
SI (1) SI3292153T1 (enExample)
SM (1) SMT201900598T1 (enExample)
WO (1) WO2016177846A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110461357A (zh) 2017-02-28 2019-11-15 阿菲姆德股份有限公司 抗cd16a抗体与细胞因子的组合
JP7115758B2 (ja) * 2017-02-28 2022-08-09 アッフィメッド・ゲー・エム・ベー・ハー Ｃｄ１６ａ指向性ｎｋ細胞エンゲージメント用タンデムダイアボディ
CN109706163A (zh) * 2017-10-26 2019-05-03 深圳新诺微环生物科技有限公司 微环dna表达连接人与动物靶细胞与效应细胞的桥接分子及其应用
CN109706164A (zh) * 2017-10-26 2019-05-03 深圳新诺微环生物科技有限公司 微环dna表达连接人和猴cd20与效应细胞抗原的桥接分子及其应用
CA3090464A1 (en) * 2018-03-14 2019-09-19 Affimed Gmbh Bispecific egfr/cd16 antigen-binding protein
MX2020010728A (es) 2018-04-13 2020-11-06 Affimed Gmbh Constructos de fusion de anticuerpos que se acoplan a celulas nk.
KR20210052494A (ko) * 2018-08-27 2021-05-10 아피메트 게엠베하 항체 구조물이 사전 로드된 동결 보존된 nk 세포
CN109402168A (zh) * 2018-10-30 2019-03-01 深圳新诺微环生物科技有限公司 微环dna表达连接her2阳性细胞与效应细胞的桥接分子及其应用
AU2020292339A1 (en) * 2019-06-11 2022-01-20 Myeloid Therapeutics, Inc. Macrophage specific engager compositions and methods of use thereof
WO2021130383A1 (en) * 2019-12-27 2021-07-01 Affimed Gmbh Method for the production of bispecific fcyriii x cd30 antibody construct
US20240343811A1 (en) 2021-06-29 2024-10-17 Shandong Simcere Biopharmacutical Co., Ltd. Cd16 antibody and use thereof
JP7503215B2 (ja) 2021-10-08 2024-06-19 ジェンマブ エー／エス Ｃｄ３０及びｃｄ３に結合する抗体
US20240424099A1 (en) * 2021-11-04 2024-12-26 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and multispecific engagers
WO2023080895A1 (en) * 2021-11-04 2023-05-11 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and multispecific engagers
CN116059348A (zh) * 2022-09-16 2023-05-05 四川大学华西医院 基于nkg2d的细胞接合器分子在清除衰老细胞中的应用
AU2023404602A1 (en) 2022-11-29 2025-05-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Cldn18.2/4-1bb binding protein and medical use thereof
TW202506178A (zh) 2023-04-05 2025-02-16 丹麥商珍美寶股份有限公司 包含與ｃｄ３０和ｃｄ３結合之抗體之醫藥組成物
CN117442721B (zh) * 2023-12-20 2024-03-15 苏州艾凯利元生物科技有限公司 一种包括nk细胞和nk细胞接合器分子的组合物
CN118791616A (zh) * 2024-09-14 2024-10-18 苏州为度生物技术有限公司天津分公司 一种抗人cd16工程抗体及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
EP3130350A1 (en) * 2005-06-08 2017-02-15 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2016029073A2 (en) * 2014-08-22 2016-02-25 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody

Also Published As

Publication number Publication date
SMT201900598T1 (it) 2020-01-14
RS59489B1 (sr) 2019-12-31
DK3292153T3 (da) 2019-10-21
AU2016257334B2 (en) 2021-08-12
US11167029B2 (en) 2021-11-09
CN107847587B (zh) 2020-10-09
CA2983706C (en) 2024-01-02
PT3292153T (pt) 2019-11-05
RU2761352C2 (ru) 2021-12-07
LT3292153T (lt) 2019-11-11
EP3292153B1 (en) 2019-07-31
CY1122283T1 (el) 2020-11-25
RU2017137251A3 (enExample) 2019-10-10
CA2983706A1 (en) 2016-11-10
ES2754557T3 (es) 2020-04-20
JP2018514576A (ja) 2018-06-07
US20180085456A1 (en) 2018-03-29
HUE045866T2 (hu) 2020-01-28
JP6609784B2 (ja) 2019-11-27
RU2017137251A (ru) 2019-06-04
PL3292153T3 (pl) 2020-02-28
AU2016257334A1 (en) 2017-11-09
CA3219372A1 (en) 2016-11-10
CN107847587A (zh) 2018-03-27
SI3292153T1 (sl) 2020-01-31
WO2016177846A1 (en) 2016-11-10
HK1253022A1 (zh) 2019-06-06
BR112017023579A2 (pt) 2018-07-24
EP3292153A1 (en) 2018-03-14

Similar Documents

Publication Publication Date Title
HRP20191933T1 (hr) Kombinacija anti-cd30xcd16a antitijela s antagonističkim anti-pd-1 antitijelom za terapiju
JP2018514576A5 (enExample)
CY1124190T1 (el) Anti-ctla4 μονοκλωνικο αντισωμα ή το θραυσμα δεσμευσης αντιγονου αυτου, φαρμακευτικη συνθεση και χρηση
ZA202104246B (en) Humanized anti-human-pd-1 antibody
PH12017502129A1 (en) Antibodies against ox40 and uses thereof
SG10201810507WA (en) Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
MX2019010172A (es) Combinacion de un anticuerpo anti-cd16a con una citocina.
HK1249423A1 (zh) 能够结合b7-h3和cd3的双特异性单价双抗体及其用途
MX2021006428A (es) Anticuerpos anti-claudina 18.2 y anti-4-1bb biespecificos y su uso.
PH12017501372A1 (en) Tnfrsf-binding agents and uses thereof
ZA201708265B (en) Tigit-binding agents and uses thereof
GEP20227419B (en) Pd-1-binding molecules and methods of use thereof
MX2018006072A (es) Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
PH12017501166B1 (en) Antibodies to tigit
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
HRP20221284T1 (hr) Anti-pvrig antitijela i postupci uporabe
MD20170031A2 (ro) Anticorpi anti-LAG3 şi fragmente de legare a antigenului
WO2017132562A8 (en) Antigen binding proteins that bind pd-l1
GEP201706794B (en) Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
AR101997A1 (es) Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos
NZ629816A (en) Therapeutic peptides
EA201892440A1 (ru) Антитела к tl1a и их применения
PH12019550194A1 (en) Anti-ceacam1 antibody and use thereof
MY195411A (en) Monospecific and Bispecific Proteins With Immune Checkpoint Regulation for Cancer Therapy
EA201792460A1 (ru) Связывающие tigit агенты и варианты их применения